Preparing For The NASH Market: A Conversation With Genfit Execs
Executive Summary
As Genfit nears Phase III data for its NASH candidate elafibranor, it has promoted a new CEO and is working ahead on both an NDA filing and facing the commercial challenges of a new therapeutic space.
You may also be interested in...
NASH Companies Take The Stage At AASLD
NGM’s injectable might be best-suited as induction therapy for sicker NASH patients, Inventiva hopes its pan-PPAR agonist will outperform Genfit’s elafibranor, and Albireo thinks IBAT inhibition offers promise in NASH.
Intercept’s NASH NDA Positions OCA For May 2020 Approval, Then Launch
Intercept hopes to be first to market in NASH with an indication to treat fibrosis. It also is enrolling a study to show a benefit in NASH patients with cirrhosis.
Genfit Addresses Multiple Transition Issues With CEO Change
Co-founder and CEO Mouney will turn over the reins to former GSK and Lilly exec Pascal Prigent in mid-September.